electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe
“We are delighted to partner with Pro Medical Baltic to be able to introduce our nVNS therapy to new patients in Eastern Europe,” said Iain Strickland, electroCore’s Vice President of European Operations. “Pro Medical Baltic already has experience working with neuromodulation products, and we look forward to supporting their market access activities for gammaCore. This agreement is hopefully the first of many that will see electroCore, Inc. expand into new markets.”
Pro Medical Baltic has been operating in these countries for five years and has an established network of leading physicians familiar with the benefits of neuromodulation. PMB currently distributes neuromodulation devices such as implantable vagus nerve stimulators and will focus on distributing gammaCore for treatment of cluster headache and refractory migraine. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, such as minimum purchase commitments.
About Pro Medical Baltic
Pro Medical Baltic is a wholesale medical supplier of a wide range of medical devices and medical equipment for hospitals and healthcare centers. Pro Medical Baltic is committed to introducing and promoting the newest methods of treatment for neurological conditions using neuromodulation devices.
For more information, visit http://www.pmbaltic.eu/
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.
gammaCore is FDA cleared in
- Safety and efficacy of gammaCore have not been evaluated in the following patients:
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
- Patients should not use gammaCore if they:
- Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
- Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.
Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in